MediWound Ltd. (NASDAQ:MDWD) Receives Consensus Recommendation of “Hold” from Analysts

Shares of MediWound Ltd. (NASDAQ:MDWD) have received a consensus rating of “Hold” from the five ratings firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $33.00.

Several equities research analysts have commented on the company. Weiss Ratings cut MediWound from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, September 8th. Oppenheimer reissued an “outperform” rating and issued a $30.00 price objective (down from $32.00) on shares of MediWound in a report on Friday, August 14th. HC Wainwright reiterated a “buy” rating and issued a $36.00 target price on shares of MediWound in a research note on Thursday, May 28th. Wall Street Zen cut shares of MediWound from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Finally, Alliance Global Partners restated a “buy” rating on shares of MediWound in a research report on Wednesday, September 16th.

Insider Activity

In other MediWound news, COO Shmuel Hess sold 3,958 shares of MediWound stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $12.92, for a total value of $51,137.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 9.20% of the company’s stock.

Institutional Trading of MediWound

Several institutional investors and hedge funds have recently modified their holdings of MDWD. Clal Insurance Enterprises Holdings Ltd increased its position in MediWound by 22.8% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 71,000 shares of the biopharmaceutical company’s stock worth $1,311,000 after purchasing an additional 13,196 shares in the last quarter. UBS Group AG boosted its stake in shares of MediWound by 90.1% during the fourth quarter. UBS Group AG now owns 145,057 shares of the biopharmaceutical company’s stock valued at $2,678,000 after purchasing an additional 68,756 shares in the last quarter. Finally, Silverberg Bernstein Capital Management LLC raised its holdings in MediWound by 8.7% in the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 200,005 shares of the biopharmaceutical company’s stock valued at $3,222,000 after buying an additional 16,081 shares during the last quarter. 46.83% of the stock is currently owned by institutional investors.

MediWound Stock Up 4.8%

Shares of NASDAQ MDWD opened at $13.95 on Wednesday. MediWound has a twelve month low of $12.52 and a twelve month high of $20.03. The stock has a market cap of $179.26 million, a price-to-earnings ratio of -7.75 and a beta of 0.14. The company’s fifty day moving average is $13.70 and its 200-day moving average is $15.13.

MediWound (NASDAQ:MDWD) last issued its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.01). MediWound had a negative return on equity of 47.24% and a negative net margin of 170.10%.The business had revenue of $3.09 million for the quarter, compared to analyst estimates of $2.59 million. On average, research analysts anticipate that MediWound will post -2.31 EPS for the current fiscal year.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative enzymatic therapies for tissue injury and wound care. The company’s products are designed to remove damaged or nonviable tissue while helping preserve healthy tissue, supporting wound management and healing.

MediWound’s lead commercial product is NexoBrid, a topical bromelain-based therapy used for the enzymatic removal of eschar in adults with deep partial-thickness and full-thickness thermal burns.